Allogene Therapeutics, Inc.

ALLO Nasdaq CIK: 0001737287

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
Business Address 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Phone (650) 457-2700
Fiscal Year End 1231
EIN 823562771

Financial Overview

FY2025

$75.22M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 13, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Pioneering "off-the-shelf" allogeneic CAR T-cell therapies for cancer, offering greater accessibility and scalability.
  • Improved net loss in 2025 ($350 million) from 2024 ($380 million) due to strategic cost-cutting and prioritization.
View Analysis

Insider Trading

STRONG SELL 6 insiders 10 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.